TREATMENT OF RAYNAUD SYNDROMES WITH PIRACETAM(NOOTROPIL R),NOOTROPIC AND ANIPLATELET AGENT

Three prospective studies have been performed with piracetam (Nootropil ®-) in the treatment of Raynaud disease and syndromes.

The first one, realized in 20 cases of Raynaud disease established that 8 g piracetam daily was the optimal dosage necessary to obtain a significant clinical, ultrasonic and biologic improvement.

In the second one, 58 cases of Raynaud syndromes (47 idiopathic and 11 associated with systemic disease) were treated with 8 g daily piracetam during 6 to 12 months. A clinical and ultrasonic improvement was observed in 75 and 80 % of the cases and a normalisation of the disturbed platelet functions (36/58) in 88 %. Moreover a benefic rheologic effect was noted and related to the membrane deformability, the antiplatelet and the Von Willebranc factor synthese or release inhibiting activity of piracetam

The third one realized in cross over in 30 cases of Raynaud syndromes compare the effects of piracetam alone (dosage 8 g daily) with the combination piracetam (4 g daily) - aspirin (100 mg daily) or with other drugs like buflomedil, calcium antagonists and ketanserine.

A synergic effect was obtained with the combination piracetam -aspirine and piracetam alone seems to be more efficient than the other drugs.

A fourth double blind study is actually performed